Gary Raskob to Kaplan-Meier Estimate
This is a "connection" page, showing publications Gary Raskob has written about Kaplan-Meier Estimate.
Connection Strength
0.378
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
Score: 0.137
-
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
Score: 0.067
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.036
-
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
Score: 0.025
-
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
Score: 0.025
-
Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
Score: 0.024
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
Score: 0.023
-
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
Score: 0.021
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.019